Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy

Amid the debut of positive Phase I data for ABS-201, Absci will progress the candidate in endometriosis and pattern hair loss. Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss. Absci will use the funds to progress its lead candidate, ABS-201, in endometriosis and pattern hair loss. Credit: Visual Generation / Shutterstock.com. Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, leaving the biopharma company poised to push the drug’s clinical development…

Source: Clinical Trials Arena